Sv2B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The SV2B Gene (Synaptic Vesicle Glycoprotein 2B) encodes a member of the synaptic vesicle glycoprotein 2 (SV2) family, which are integral membrane proteins essential for synaptic vesicle function and neurotransmitter release. SV2B plays critical roles in synaptic transmission, vesicle cycling, and has been implicated in various neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
| SV2B - Synaptic Vesicle Glycoprotein 2B |
|---|
| Full Name | Synaptic Vesicle Glycoprotein 2B |
| Chromosome | 15q21.2 |
| NCBI Gene ID | 9908 |
| OMIM ID | 617056 |
| Ensembl ID | ENSG00000122012 |
| UniProt ID | Q9H0Y5 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Epilepsy, Intellectual Disability, Bipolar Disorder |
SV2B is a type I transmembrane protein with a unique architecture:
- N-terminal large lumenal domain (~600 amino acids): Contains multiple N-glycosylation sites and conserved cysteines
- Short cytoplasmic tail (~50 amino acids): Contains trafficking signals
- Single transmembrane helix: Anchors the protein in synaptic vesicle membrane
The SV2 family includes three major isoforms:
- SV2A: Ubiquitously expressed in all synaptic vesicles
- SV2B: Brain-specific, primarily in excitatory synapses
- SV2C: Basal ganglia-enriched expression
SV2B is involved in multiple stages of the synaptic vesicle cycle:
- Vesicle Priming: SV2 proteins interact with synaptotagmin and SNARE complexes to prepare vesicles for release[1]
- Calcium Sensing: Modulates the calcium sensitivity of neurotransmitter release
- Vesicle Recycling: Facilitates clathrin-mediated endocytosis of synaptic vesicles
- Vesicle Replenishment: Helps maintain the readily releasable pool of vesicles
SV2B interacts with several key synaptic proteins:
- Synaptotagmin-1: Calcium sensor for exocytosis
- SNARE proteins (Syntaxin-1A, SNAP-25, Synaptobrevin-2): Core exocytic machinery
- Munc13: Vesicle priming factor
- RIM: Active zone scaffold protein
- Synaptojanin 1: Phosphatase involved in vesicle endocytosis[2]
SV2B shows region-specific expression in the brain:
| Brain Region |
Expression Level |
Cell Type |
| Hippocampus |
High |
Pyramidal neurons, interneurons |
| Cerebral Cortex |
High |
Layer 2/3 pyramidal neurons |
| Cerebellum |
High |
Purkinje cells, granule cells |
| Basal Ganglia |
Moderate |
Striatal medium spiny neurons |
| Thalamus |
Moderate |
Relay neurons |
| Brainstem |
Low-Moderate |
Various neuron types |
- Presynaptic terminals: Highly concentrated in synaptic vesicles
- Dendritic shafts: Present in some dendritic compartments
- Cell bodies: Low levels in neuronal soma
SV2B plays a significant role in AD pathogenesis:
- Synaptic Loss: SV2B expression is reduced in AD brain, correlating with cognitive decline[3]
- Amyloid Pathology: Aβ oligomers disrupt SV2B trafficking and function
- Tau Pathology: Hyperphosphorylated tau affects SV2B-containing vesicle pools
- Therapeutic Target: SV2B modulators may restore synaptic function in AD
SV2B involvement in PD:
- Dopaminergic Terminals: SV2B is expressed in substantia nigra pars compacta neurons
- Alpha-Synuclein Interaction: α-syn aggregates may disrupt SV2B function
- Vesicular Dysfunction: Impaired neurotransmitter release in PD models
- Biomarker Potential: SV2B levels in CSF as PD progression marker
- Seizure Threshold: SV2B knockout mice show altered seizure susceptibility[4]
- Synaptic Hyperexcitability: Reduced inhibition due to impaired vesicle cycling
- Therapeutic Implications: SV2B modulators may have antiepileptic potential
- Synaptic Development: SV2B required for proper synapse formation
- Cognitive Function: SV2B haploinsufficiency associated with intellectual disability
- Neurodevelopmental Disorders: Altered expression in autism spectrum disorders
- Synaptic vesicles synthesize and load neurotransmitters
- Vesicles undergo priming at active zones (SV2B involved)
- Calcium influx triggers exocytosis (synaptotagmin-SV2B interaction)
- Vesicle membrane retrieved via clathrin-mediated endocytosis
- SV2B recycled back to synaptic vesicles
- Cycle repeats for sustained transmission
- Protein kinase A (PKA): Phosphorylation modulates SV2B trafficking
- Calcium/calmodulin-dependent protein kinase II (CaMKII): Regulates SV2B function during plasticity
- Casein kinases: Control SV2B synaptic vesicle localization
- SV2B Agonists: Enhance synaptic function in neurodegeneration
- Positive Allosteric Modulators: Increase vesicle release probability
- Gene Therapy: AAV-mediated SV2B expression in affected neurons
- Protein Stabilizers: Protect SV2B from Aβ-induced dysfunction
- Blood-Brain Barrier: Small molecule modulators must cross BBB
- Selectivity: SV2B vs SV2A/SV2C isoform specificity important
- Delivery: Viral vectors for gene therapy approaches
- Jackman SL, et al. (2016). "Synaptotagmin-1 and synaptotagmin-7 trigger asynchronous neuron excitation". Nature. PMID:27462455[1]
- Cao M, et al. (2019). "Synaptojanin 1 regulates synaptic vesicle endocytosis". J Neurosci. PMID:31748261[2]
- Mattsson N, et al. (2017). "Synaptic proteins in CSF as biomarkers for neurodegeneration". Nat Rev Neurol. PMID:28280218[3]
- Crowder KM, et al. (2002). "Abnormal neurotransmission in mice lacking synaptic vesicle protein 2B (SV2B)". Proc Natl Acad Sci. PMID:11836291[4]
- Moulder KL, et al. (2006). "Distinct structural features of SV2B regulate its interaction with synaptotagmin". J Biol Chem. PMID:16497724
- Dittinger E, et al. (2017). "SV2B mutations cause a new form of congenital myasthenic syndrome". Brain. PMID:28082398
- Jiang CH, et al. (2020). "The effects of SV2B on amyloid-beta induced synaptic dysfunction". Mol Neurobiol. PMID:32975623
- Xiong M, et al. (2021). "Synaptic vesicle glycoprotein 2 family in neurodegenerative diseases". Front Cell Neurosci. PMID:34149369
The study of Sv2B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Jackman SL, et al. (2016). Synaptotagmin-1 and synaptotagmin-7 trigger asynchronous neuron excitation. Nature. 536:108-112. PMID:27462455
- Cao M, et al. (2019). Synaptojanin 1 regulates synaptic vesicle endocytosis. J Neurosci. 39:7692-7704. PMID:31748261
- Mattsson N, et al. (2017). Synaptic proteins in CSF as biomarkers for neurodegeneration. Nat Rev Neurol. 13:577-588. PMID:28280218
- Crowder KM, et al. (2002). Abnormal neurotransmission in mice lacking synaptic vesicle protein 2B (SV2B). Proc Natl Acad Sci USA. 99:7836-7841. PMID:11836291
- Moulder KL, et al. (2006). Distinct structural features of SV2B regulate its interaction with synaptotagmin. J Biol Chem. 281:8768-8774. PMID:16497724
- Dittinger E, et al. (2017). SV2B mutations cause a new form of congenital myasthenic syndrome. Brain. 140:2825-2839. PMID:28082398
- Jiang CH, et al. (2020). The effects of SV2B on amyloid-beta induced synaptic dysfunction. Mol Neurobiol. 57:4799-4809. PMID:32975623
- Xiong M, et al. (2021). Synaptic vesicle glycoprotein 2 family in neurodegenerative diseases. Front Cell Neurosci. 15:750889. PMID:34149369
- Zhang Y, et al. (2018). SV2B polymorphisms and susceptibility to Parkinson's disease. Neurosci Lett. 674:99-103. PMID:29539521
- Liu L, et al. (2019). Role of SV2A and SV2B in epileptogenesis. Epilepsy Res. 155:106140. PMID:31272098